Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe the metabolic side effects of a common diabetes drug

NCT ID NCT05960656

Recruiting now Knowledge-focused Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates how the diabetes medication empagliflozin (an SGLT2 inhibitor) increases ketone production and fat breakdown in people with type 2 diabetes. Researchers will also test whether another drug, pioglitazone, can prevent these effects. The goal is to understand the mechanisms behind these metabolic changes, which could help improve the safety of SGLT2 inhibitors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin (SGLT2 inhibitor) and pioglitazone (thiazolidinedione)
What this could lead to
If successful, this research could clarify how SGLT2 inhibitors trigger ketone production, potentially leading to safer use of these drugs and new strategies to prevent ketoacidosis.
What could go wrong
This is an early-phase, small study (30 people) focused on understanding biological mechanisms, not on treating disease. Results may not translate into clinical practice or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Diabetes Institute/UH

    RECRUITING

    San Antonio, Texas, 78229-3900, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.